Skip to main content
. 2021 Oct 21;12(6):2211–2219. doi: 10.1002/jcsm.12837

Table 1.

Baseline characteristics

High CXI (n = 173) Intermediate CXI (n = 36) Low CXI (n = 57) P
Age
Median (IQR), years 62 (49–70) 67 (58–74.5) 73 (64–76) <0.001
≤40 years 20 (11.6) 2 (5.6) 2 (3.5) <0.001
41–60 years 65 (37.6) 10 (27.8) 8 (14.0)
61–74 years 67 (38.7) 15 (41.7) 25 (43.9)
≥75 years 21 (12.1) 9 (25.0) 22 (38.6)
Sex
Male 98 (56.7) 19 (52.8) 33 (57.9) 0.951
Female 75 (43.4) 17 (47.2) 24 (42.1)
ECOG PS
0–1 140 (80.9) 24 (66.7) 26 (45.6) <0.001
2–3 33 (19.1) 12 (33.3) 31 (54.4)
B‐symptoms
Absent 151 (87.3) 29 (80.6) 39 (68.4) 0.001
Present 22 (12.7) 7 (19.4) 18 (31.6)
Median BMI (IQR), kg/m2 23.4 (21.5–25.5) 22.7 (21.4–25.1) 22.7 (20.0–24.8) 0.137
Bulky disease
Non‐bulky 138 (79.8) 31 (86.1) 46 (80.7) 0.739
Bulky 35 (20.2) 5 (13.9) 11 (19.3)
Ann Arbor stage
I–II 86 (49.7) 13 (36.1) 13 (22.8) <0.001
III–IV 87 (50.3) 23 (63.9) 44 (77.2)
Extranodal disease
Absent 68 (39.3) 14 (38.9) 15 (26.3) 0.098
Present 105 (60.7) 22 (61.1) 42 (73.7)
LDH, normalized
Normal 88 (50.9) 11 (30.6) 9 (15.8) <0.001
>1 to ≤3 76 (43.9) 19 (52.8) 31 (54.4)
>3 9 (5.2) 6 (16.7) 17 (29.8)
NCCN‐IPI
Low 23 (13.3) 1 (2.8) 1 (1.8) <0.001
Low‐intermediate 79 (45.7) 10 (27.8) 5 (8.8)
High‐intermediate 52 (30.1) 19 (52.8) 19 (33.3)
High 19 (11.0) 6 (16.7) 32 (56.1)
Cell‐of‐origin (n = 174)
GCB 27 (24.8) 3 (15.8) 16 (34.8) 0.266
Non‐GCB 82 (75.2) 16 (84.2) 30 (65.2)

Abbreviations: BMI, body mass index; CXI, cachexia index; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B‐cell; IQR, interquartile range; LDH, lactate dehydrogenase; NCCN‐IPI, National Comprehensive Cancer Network‐International Prognostic Index.

Data are presented as number of patients (%) except median age and BMI.